Is It Time to Buy Humana Inc.'s Stock?

Humana Inc.'s (HUM) shares have been on a roll this year, but that doesn't guarantee there's room to run.

Sep 4, 2014 at 10:18AM


Source: Humana.

About three-quarters of Humana Inc.'s (NYSE:HUM) revenue comes from Medicare Advantage members, far more than competing insurers such as UnitedHealth Group or WellPoint. That means that Humana's success or failure is more closely tied to whether aging baby boomers select a Medicare Advantage or Medi-Gap supplemental insurance plan.

Since 10,000 boomers will turn 65 daily through 2029, there will be plenty of opportunity for Humana sales to grow, but that may not mean that now is the right time to buy Humana's stock. Having said that, let's take a closer look at whether Humana's shares may make sense today.

Debating earnings
Humana's Medicare Advantage membership jumped 16.4%, or by 333,000 people, to 2.36 million over the past year. That's helped sales climb from $7.5 billion in the second quarter of 2013 to $8.8 billion in the second quarter of 2014.

However, the ability to translate that revenue growth into earnings is probably more important to shareholders, and Humana's earnings forecast isn't overly encouraging.

Although competitors such as WellPoint are guiding for earnings growth this year, Humana is predicting that its earnings may fall. The company expects earnings per share of between $7.25 and $7.75 this year, which at the midpoint would represent a drop from the $7.73 per share it earned last year.

Humana Exterior Angle

Source: Humana

That has dented Wall Street expectations. Over the past 90 days, analysts have reduced their estimate for Humana's earnings per share this year from $7.80 to $7.73.

However, analysts remain optimistic about 2015. They've increased their outlook for 2015 from $8.74 to $8.78.

That disconnect may suggest that industry watchers expect that either Humana is downplaying its potential profit for this year, or that Medicare Advantage plan demand and pricing will be better next year than it is this year.

It could also suggest that Humana's individual plans, which represent a small portion of Humana's overall sales, could have more of an impact on profit next year. After all, ACA enrollment did help lift the company's non-Medicare individual plan membership by 122% during the first two quarters of 2014.

Debating valuation
No one will ever confuse Humana with a high-growth technology stock. Insurer profit margins are notoriously thin, and as a result, investors tend to value them more cheaply than they do growth stocks.

That's clearly the case when it comes to Humana's price-to-sales ratio. Even though Humana is trading at just 0.45 trailing-12-month sales, which is cheap by technology stock standards, that ratio is just about at a five-year high. The situation is similar at WellPoint, because both of these stocks have made a huge move in the past year.

WLP PS Ratio (TTM) Chart

WLP PS Ratio (TTM) data by YCharts

Price-to-earnings ratios paint a similar picture. Humana is trading at nearly 16.5 times next year's expected earnings per share, which is just about a new 10-year high. That would suggest there's not a lot of room, in terms of valuation, for Humana to run higher, at least not without a boost to guidance.

Fool-worthy final thoughts
There's plenty to like about insurers, given that exchanges exceeded industry projections, pricing will head higher next year, and Medicaid expansion continues to gain a foothold.

However, that opportunity may be fairly well reflected in current share prices. If so, that would suggest that investors considering new positions in these companies may want to wait patiently for a pullback. 

Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend-paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers